BeiGene Ltd. ADR (BGNE) News
Filter BGNE News Items
BGNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BGNE News Highlights
- BGNE's 30 day story count now stands at 6.
- Over the past 9 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about BGNE are DRUG, KHC and LE.
Latest BGNE News From Around the Web
Below are the latest news stories about BEIGENE LTD that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
12 High Growth International Stocks to BuyIn this article, we discuss the 12 high growth international stocks to buy. If you want to read about some more high growth international stocks, go directly to 5 High Growth International Stocks to Buy. There is general optimism on Wall Street that the Federal Reserve in the United States will be able to achieve […] |
FDA Approves Label Update for BRUKINSA® (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 22, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved a label update for BRUKINSA® (zanubrutinib) to include superior progression-free survival (PFS) results from the Phase 3 ALPINE trial comparing BRUKINSA against IMBRUVICA® (ibrutinib) in previously treated patients with relapsed or refractory (R/R) chronic lymphocytic le |
3 Cancer-Focused Biotechs That Appear Promising Bets for 2024With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024. |
BeiGene to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., December 21, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8th, 2024 with a presentation at 1:30 pm PT. |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
5 Nasdaq Composite Laggards Likely to Gather Pace in 2024We have narrowed our search to five Nasdaq Composite listed laggards of 2023 with strong potential for 2024. These are: PEP, KHC, WMG, PODD, BGNE. |
Lilly (LLY) Gets Second FDA Nod for Lymphoma Drug JaypircaFollowing the latest approval, Lilly's (LLY) Jaypirca is the first and the only non-covalent BTK inhibitor to extend the benefit of targeting the BTK pathway. |
Wall Street Analysts Think BeiGene, Ltd. (BGNE) Could Surge 44.28%: Read This Before Placing a BetThe mean of analysts' price targets for BeiGene, Ltd. (BGNE) points to a 44.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
BeiGene to Host ASH Investor Meeting in Person and via Webcast on December 10, 2023BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 29, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it will host an Investor Event at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego and via webcast at 8:00 PM PST on December 10, 2023. This event will cover BeiGene’s R&D progress and broad hematology portfolio, with invited speakers presenting key data from the ASH 2023. |
BeiGene to Present New Data Highlighting Hematology Portfolio and Pipeline Strengths at ASH 2023BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass., November 28, 2023--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the presentation of new data across a range of assets and blood cancers at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 9-12 in San Diego, California. BeiGene has 24 abstracts accepted at ASH, with three abstracts scheduled for oral presentations. |